TURALIO NOW APPROVED
Introducing TURALIO™ (pexidartinib): The first and only FDA-approved treatment for tenosynovial giant cell tumor (TGCT)1*

*TGCT is also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma: Pexidartinib (TURALIO) is the first and only systemic therapy with a category 1 recommendation for TGCT.

A category 1 recommendation indicates that based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

The NCCN recommends that prior to the initiation of treatment, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma.

Indication and Usage

TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Please click here for full Prescribing Information, including Boxed WARNING, and click here for Medication Guide.

See the press release.

Prescribing TURALIO TURALIO is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), because of the risk of hepatotoxicity. In order to prescribe TURALIO, a healthcare provider must become certified. To receive TURALIO, patients must also enroll in the TURALIO REMS patient registry.

Become REMS-Certified

TGCT Treatment Centers Locate healthcare professionals certified to prescribe TURALIO and other centers that may treat TGCT.

FIND TGCT TREATMENT CENTERS NOW